Anaes · Anaesthetic adjuncts
Alpha-2 agonists — dexmedetomidine and clonidine
Also known as Dexmedetomidine · Clonidine · Selective alpha-2 adrenergic agonist · Gi-coupled alpha-2 receptor agonist · Arousable (cooperative) sedative
The selective alpha-2 adrenergic agonists — dexmedetomidine and clonidine — are the sedative class with cooperative, arousable sedation and minimal respiratory depression (Weerink 2017), and mastery of them resolves a large block of the applied pharmacology syllabus. The framework rests on four exam-critical ideas: the alpha-2 receptor is a Gi-coupled GPCR acting as presynaptic autoreceptor (sympatholysis), locus-coeruleus sedation mimicking natural sleep with patients rousable and cooperative, and spinal analgesia with opioid-sparing (Weerink 2017; Bajwa 2013); dexmedetomidine is highly selective (alpha-2 to alpha-1 ratio 1620 to 1) with transient hypertension, bradycardia and hypotension from peripheral vasoconstriction plus sympatholysis, hepatic glucuronidation/hydroxylation to inactive metabolites, and intranasal/buccal adjuvant use (Weerink 2017); ICU sedation needs less rescue propofol/midazolam and less morphine with calmer arousable patients, and procedural sedation is effective for awake fibreoptic intubation and monitored care (Hoy 2011); and roles span ICU weaning, procedural and awake-fibreoptic sedation, anaesthetic-sparing (Twinkle 2026 infratentorial 1 mcg/kg over 10 min plus 0.4 mcg/kg/h with lower MAP/isoflurane/fentanyl), regional adjuvant prolongation (Grelowska 2026 ESPB TKA time-to-first-opioid 13.70/12.40 vs 7.85 h), and clonidine opioid-sparing (de Souza 2026 hernia VAS 0 vs 2, plus 2.0 h pain-free, RR 0.59 rescue). Sleep-bundle context (Joseph 2026) and dex-containing multimodal procedural numbers (Liu 2026) are scoped principles, not dex-alone dosing. Doses are taught-formulary.
Practise this topic
On this page
Study tools
Your progress
Saved on this device.
Target exams
Red flags
- Dexmedetomidine causes BRADYCARDIA that can be severe and is vagally mediated through sympatholysis. It can produce high-grade atrioventricular block and asystole in the patient with pre-existing conduction disease, heart block, or severe beta-blockade, and in the hypovolaemic or vagotonic patient. It is relatively contraindicated in advanced heart block and must be used with caution in the patient on a negative chronotrope; have an anticholinergic (atropine or glycopyrrolate) immediately available.
- RAPID intravenous loading causes transient HYPERTENSION and reflex bradycardia. A bolus given too quickly stimulates peripheral alpha-1 (and alpha-2) vascular receptors before the central sympatholysis dominates, producing a transient vasoconstriction and blood-pressure rise. Always administer the loading dose SLOWLY over 10 minutes, reduce or omit the loading dose in the haemodynamically fragile or elderly patient, and never give dexmedetomidine as a rapid push.
- Dexmedetomidine does NOT provide amnesia, anterograde or otherwise. Unlike the benzodiazepines it cannot be relied upon to prevent awareness, and where amnesia is required (a stimulus-rich awake procedure) a low dose of a benzodiazepine, propofol or a volatile must supplement it. The absence of amnesia is a defining pharmacodynamic difference and a classic exam point.
- Dexmedetomidine is a potent sympatholytic and its hypotension is compounded by hypovolaemia. In the volume-depleted or vasodilated patient (sepsis, spinal anaesthesia, after anaesthetic induction) the loss of sympathetic tone can produce a profound and refractory hypotension; correct intravascular volume first and titrate cautiously.
- Although dexmedetomidine spares respiration, it potentiates the respiratory depressant effect of co-administered opioids, benzodiazepines and propofol. The class-sparing property is true only for the agent used ALONE; combined sedation still requires airway monitoring and the capacity for rescue.
Meet the patient
A 68-year-old man is ventilated in ICU for pneumonia. He is improving, but every time you turn the midazolam down to wean, he becomes agitated and delirious. You need a sedative that lets him breathe, cooperate with neurological examination, and does not feed the delirium.[8]
The drug that fits is dexmedetomidine — with cooperative sedation, minimal respiratory depression, less rescue propofol/midazolam and less morphine than placebo, and calmer, easier-to-arouse patients (Hoy 2011). Sleep-hygiene bundles including dexmedetomidine in specific ICU populations can reduce delirium by 30 to 50 percent and shorten ICU stay by about 1.2 days (Joseph 2026) — a bundle principle, not dex-alone dosing.[8][3]
References8ShowHide
- [1]Grelowska E, et al. Dexamethasone vs. Dexmedetomidine as Adjuvants to Erector Spinae Plane Block in Total Knee Arthroplasty: A Randomized Double-Blind Controlled Trial J Clin Med, 2026.PMID 42355681
- [2]Twinkle, et al. Role of Dexmedetomidine on Hemodynamics and Anesthetic Requirement in Patients Undergoing Elective Infratentorial Tumor Surgery: A Prospective, Randomized, Double-blind, Placebo-controlled Study Ann Afr Med, 2026.PMID 41947379
- [3]Joseph J, et al. Evidence-Based Intervention for Sleep Deprivation in the Intensive Care Unit: A Clinical Review Florence Nightingale J Nurs, 2026.PMID 42364187
- [4]Liu X, et al. Evaluation of intravenous sedation in dental implant surgeries: A prospective cohort study J Dent, 2026.PMID 42364899
- [5]de Souza PMF, et al. Opioid-sparing analgesia with clonidine versus fentanyl in inguinal hernia repair: a randomized clinical trial Hernia, 2026.PMID 42364024
- [6]Weerink MAS, et al. Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine. Clin Pharmacokinet, 2017.PMID 28105598
- [7]Bajwa S, et al. Dexmedetomidine: an adjuvant making large inroads into clinical practice. Ann Med Health Sci Res, 2013.PMID 24379995
- [8]Hoy SM, et al. Dexmedetomidine: a review of its use for sedation in mechanically ventilated patients in an intensive care setting and for procedural sedation. Drugs, 2011.PMID 21812509